GeoVax Labs (GOVX) vs Kairos Pharma (KAPA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kairos Pharma is the larger company by market cap ($3.4 million vs $2.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GOVX | KAPA |
|---|---|---|
| Share price | $0.2875 | $0.99 |
| Market cap | $2.90M | $3.35M |
| 1-day change | +0.31% | +3.18% |
| EPS (TTM) | $-8.84 | $-1.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.75 | $9.24 |
| 52-week low | $0.2705 | $0.848 |
| Distance from 52-week high | -98.17% | -89.29% |
| Analyst consensus | none | none |
| Avg. price target upside | +3378.26% | +4849.49% |
| Average volume | 771.47K | 602.89K |
| Shares outstanding | 10.10M | 3.39M |
| Employees | 19 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About GeoVax Labs
GOVX stock →GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Kairos Pharma
KAPA stock →Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
GOVX vs KAPA FAQ
Which is bigger, GeoVax Labs or Kairos Pharma?
Kairos Pharma (KAPA) is larger, with a market capitalization of $3.35M compared with $2.90M for GeoVax Labs (GOVX).
Are GeoVax Labs and Kairos Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.